241 related articles for article (PubMed ID: 7055275)
1. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.
Goodwin FK; Prange AJ; Post RM; Muscettola G; Lipton MA
Am J Psychiatry; 1982 Jan; 139(1):34-8. PubMed ID: 7055275
[TBL] [Abstract][Full Text] [Related]
2. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.
Joffe RT; Singer W
Psychiatry Res; 1990 Jun; 32(3):241-51. PubMed ID: 2201988
[TBL] [Abstract][Full Text] [Related]
3. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature.
Altshuler LL; Bauer M; Frye MA; Gitlin MJ; Mintz J; Szuba MP; Leight KL; Whybrow PC
Am J Psychiatry; 2001 Oct; 158(10):1617-22. PubMed ID: 11578993
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.
Joffe RT; Singer W; Levitt AJ; MacDonald C
Arch Gen Psychiatry; 1993 May; 50(5):387-93. PubMed ID: 8489327
[TBL] [Abstract][Full Text] [Related]
5. Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation.
Garbutt JC; Mayo JP; Gillette GM; Little KY; Mason GA
Am J Psychiatry; 1986 Aug; 143(8):1038-9. PubMed ID: 3089033
[TBL] [Abstract][Full Text] [Related]
6. Tricyclic antidepressant plasma levels: the state of the art and clinical prospects.
Razavi D; Mendlewicz J
Neuropsychobiology; 1982; 8(2):73-85. PubMed ID: 7070646
[TBL] [Abstract][Full Text] [Related]
7. Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics.
Magni G; Garreau M; Orofiamma B; Palminteri R
Neuropsychobiology; 1989; 20(3):126-31. PubMed ID: 2668780
[TBL] [Abstract][Full Text] [Related]
8. An open study of triiodothyronine augmentation of tricyclic antidepressants in inpatients with refractory depression.
Birkenhäger TK; Vegt M; Nolen WA
Pharmacopsychiatry; 1997 Jan; 30(1):23-6. PubMed ID: 9065966
[TBL] [Abstract][Full Text] [Related]
9. Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression.
Kocsis JH; Croughan JL; Katz MM; Butler TP; Secunda S; Bowden CL; Davis JM
Am J Psychiatry; 1990 May; 147(5):621-4. PubMed ID: 2183635
[TBL] [Abstract][Full Text] [Related]
10. [Psychotropic profile of essential antidepressants (amitriptyline, imipramine, desipramine, chlorimipramine): comparative study].
Koszewska I; Beresewicz M; Puzyński S; Kalinowski A
Psychiatr Pol; 1994; 28(1):27-38. PubMed ID: 8190817
[TBL] [Abstract][Full Text] [Related]
11. Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triiodothyronine.
Thase ME; Kupfer DJ; Jarrett DB
J Clin Psychiatry; 1989 Oct; 50(10):385-8. PubMed ID: 2676995
[TBL] [Abstract][Full Text] [Related]
12. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination?
Levitt AJ; Joffe RT; Kamil R; McIntyre R
J Clin Psychiatry; 1999 Sep; 60(9):613-6. PubMed ID: 10520980
[TBL] [Abstract][Full Text] [Related]
13. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system.
de Montigny C; Cournoyer G; Morissette R; Langlois R; Caillé G
Arch Gen Psychiatry; 1983 Dec; 40(12):1327-34. PubMed ID: 6418109
[TBL] [Abstract][Full Text] [Related]
14. Plasma concentrations of tricyclic antidepressants in clinical practice.
Hollister LE
J Clin Psychiatry; 1982 Feb; 43(2):66-9. PubMed ID: 7056706
[TBL] [Abstract][Full Text] [Related]
15. Tricyclic-resistant depression: treatment resistance or inadequate treatment?
Lydiard RB
J Clin Psychiatry; 1985 Oct; 46(10):412-7. PubMed ID: 3900051
[TBL] [Abstract][Full Text] [Related]
16. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse.
Rao ML; Deister A; Laux G; Staberock U; Höflich G; Möller HJ
Pharmacopsychiatry; 1996 May; 29(3):97-102. PubMed ID: 8738313
[TBL] [Abstract][Full Text] [Related]
17. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressive states.
Ogura C; Okuma T; Uchida Y; Imai S; Yogi H
Folia Psychiatr Neurol Jpn; 1974; 28(3):179-86. PubMed ID: 4435675
[No Abstract] [Full Text] [Related]
18. Failure of T3 to potentiate tricyclic antidepressant response.
Gitlin MJ; Weiner H; Fairbanks L; Hershman JM; Friedfeld N
J Affect Disord; 1987; 13(3):267-72. PubMed ID: 2960719
[TBL] [Abstract][Full Text] [Related]
19. The methylphenidate test for differentiating desipramine-responsive from nortriptyline-responsive depression.
Sabelli HC; Fawcett J; Javaid JI; Bagri S
Am J Psychiatry; 1983 Feb; 140(2):212-4. PubMed ID: 6849437
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs.
Maas JW; Koslow SH; Katz MM; Bowden CL; Gibbons RL; Stokes PE; Robins E; Davis JM
Am J Psychiatry; 1984 Oct; 141(10):1159-71. PubMed ID: 6207736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
